ALAR PHARMACEUTICALS INC.
Area: Government, Academia and Research Institutes
Booth No: M636
Website: https://alarpharm.com/
Exhibitor Profile
Alar Pharm, a new drug development company, focuses on developing long-acting release injectables (LAIs) for treating CNS disorders & chronic diseases, including opioid use disorder, alcohol use disorder, chronic pain, treatment-resistant depression, Parkinson's disease, and Schizophrenia. Our LAIs have distinctive characteristics such as low viscosity, small injection volume, and smooth drug release profile with fewer side effects, which provide better medication choices to patients.
Brands
ALAR PHARMACEUTICALS INC.
Video
Exhibit Products
-
ALA-5000, a sustained release injectable for Schizophrenia
-
ALA-1000, a sustained released buprenorphine injectable for opioid use disorder or chronic pain
-
ALA-2000, a sustained release naltrexone injectable for alcohol use disorder or opioid use disorder
-
ALA-3000, a sustained release ketamine injectable for treatment-resistant depression
-
ALA-4000, a sustained release apomorphine injectable for Parkinson's disease
-
In-Relar Techonology Platform
Exhibitors you may be interested in
Highest Rated